Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of Keytruda + Lonsurf in previously treated advanced gastric cancer
KCT0007540Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and trifluridine + tipiracil in gastric cancer (GC), sponsored by Merck & Co. Started Nov 2022; status: active, not recruiting.
02
Drugs
pembrolizumabtrifluridine + tipiracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0007540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007540.